Production (Stage)
Stoke Therapeutics, Inc.
STOK
$9.43
$0.252.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 50.27M | -88.98M | -105.46M | -103.57M | -108.53M |
| Total Depreciation and Amortization | 2.09M | 2.18M | 2.28M | 2.37M | 2.44M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.02M | 28.09M | 27.71M | 27.19M | 26.66M |
| Change in Net Operating Assets | -11.84M | -28.14M | -8.84M | -5.95M | -4.84M |
| Cash from Operations | 69.54M | -86.85M | -84.31M | -79.95M | -84.28M |
| Capital Expenditure | -343.00K | -203.00K | -390.00K | -670.00K | -1.46M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -103.49M | -107.27M | -93.13M | -48.23M | 64.31M |
| Cash from Investing | -103.83M | -107.48M | -93.52M | -48.90M | 62.85M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 130.75M | 131.09M | 137.87M | 130.27M | 9.67M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 130.75M | 131.09M | 137.87M | 130.27M | 9.67M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.46M | -63.23M | -39.96M | 1.42M | -11.76M |